Advanced glycation end-product pathway (AGE pathway)

The Advanced Glycation End-product (AGE) pathway is a biochemical cascade initiated by the non-enzymatic glycation of proteins, lipids, and nucleic acids by reducing sugars, a process known as the Maillard reaction (PMID: 31433644). This pathway leads to the accumulation of stable, irreversible AGE adducts that compromise tissue structure and function, particularly in long-lived proteins like collagen (PMID: 24053166). AGEs exert their pathological effects through two primary mechanisms: the direct cross-linking of extracellular matrix components and the activation of the Receptor for Advanced Glycation End-products (RAGE), which induces pro-inflammatory and pro-oxidative signaling via the NF-κB pathway (PMID: 22633752). This axis is heavily implicated in the progression of diabetic complications, including nephropathy and retinopathy, as well as neurodegenerative conditions like Alzheimer's disease and cardiovascular disorders (PMID: 28735874). Therapeutic interventions have historically focused on inhibiting AGE formation (e.g., aminoguanidine), breaking existing cross-links (e.g., alagebrium), or blocking RAGE signaling (e.g., azeliragon) (PMID: 24053166). While many of these agents showed promise in preclinical models, clinical success has been limited by safety concerns, such as systemic toxicity, and the difficulty of reversing established glycation-mediated damage in humans (PMID: 15132712).

Other names

Glycation pathwayMaillard reaction pathwayAGE-RAGE axisAdvanced glycation end-product signaling

Inhibition of non-enzymatic glycation, sequestration of reactive carbonyl species, cleavage of AGE-derived protein cross-links, and competitive inhibition of the Receptor for Advanced Glycation End-products (RAGE).